{"id":"https://openalex.org/W2102465598","doi":"https://doi.org/10.2174/138161209787315701","title":"Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study","display_name":"Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study","publication_year":2009,"publication_date":"2009-01-30","ids":{"openalex":"https://openalex.org/W2102465598","doi":"https://doi.org/10.2174/138161209787315701","mag":"2102465598","pmid":"https://pubmed.ncbi.nlm.nih.gov/19199980"},"language":"en","primary_location":{"id":"doi:10.2174/138161209787315701","doi":"https://doi.org/10.2174/138161209787315701","is_oa":false,"landing_page_url":"https://doi.org/10.2174/138161209787315701","pdf_url":null,"source":{"id":"https://openalex.org/S55674637","display_name":"Current Pharmaceutical Design","issn_l":"1381-6128","issn":["1381-6128","1873-4286"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Pharmaceutical Design","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064557050","display_name":"Jean-Claude Ansquer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Ansquer","raw_affiliation_strings":["Laboratoires Fournier SA, Cardiometabolic Therapeutic Area, Daix, France. jean-claude.ansquer@solvay.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratoires Fournier SA, Cardiometabolic Therapeutic Area, Daix, France. jean-claude.ansquer@solvay.com","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007228758","display_name":"Christelle Foucher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210105915","display_name":"Solvay (France)","ror":"https://ror.org/01jyh4590","country_code":"FR","type":"company","lineage":["https://openalex.org/I17170469","https://openalex.org/I4210105915"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"C. Foucher","raw_affiliation_strings":["Laboratoires Fournier SA, A Solvay Pharmaceuticals Company, 50 rue de Dijon, 21121 DAIX, France.,France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratoires Fournier SA, A Solvay Pharmaceuticals Company, 50 rue de Dijon, 21121 DAIX, France.,France","institution_ids":["https://openalex.org/I4210105915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069881677","display_name":"Patrick Aubonnet","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. Aubonnet","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5025066980","display_name":"Karine Le Malicot","orcid":"https://orcid.org/0000-0002-3226-8525","observed_orcids":["https://orcid.org/0000-0002-3226-8525"]},"institutions":[{"id":"https://openalex.org/I4210105915","display_name":"Solvay (France)","ror":"https://ror.org/01jyh4590","country_code":"FR","type":"company","lineage":["https://openalex.org/I17170469","https://openalex.org/I4210105915"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"K. Le Malicot","raw_affiliation_strings":["Laboratoires Fournier SA, A Solvay Pharmaceuticals Company, 50 rue de Dijon, 21121 DAIX, France.,France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratoires Fournier SA, A Solvay Pharmaceuticals Company, 50 rue de Dijon, 21121 DAIX, France.,France","institution_ids":["https://openalex.org/I4210105915"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5007228758","https://openalex.org/A5025066980"],"corresponding_institution_ids":["https://openalex.org/I4210105915"],"apc_list":null,"apc_paid":null,"fwci":8.2896,"has_fulltext":false,"cited_by_count":71,"citation_normalized_percentile":{"value":0.97771588,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"15","issue":"5","first_page":"537","last_page":"552"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.4147999882698059,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.4147999882698059,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.26930001378059387,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.10559999942779541,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fibrates","display_name":"fibrates","score":0.9940000176429749},{"id":"https://openalex.org/keywords/fenofibrate","display_name":"fenofibrate","score":0.9990000128746033},{"id":"https://openalex.org/keywords/microvascular-complications","display_name":"microvascular complications","score":0.7419999837875366},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9919999837875366},{"id":"https://openalex.org/keywords/diabetic-retinopathy","display_name":"diabetic retinopathy","score":0.9850000143051147},{"id":"https://openalex.org/keywords/diabetic-nephropathy","display_name":"diabetic nephropathy","score":0.9900000095367432},{"id":"https://openalex.org/keywords/diabetic-neuropathy","display_name":"diabetic neuropathy","score":0.9980000257492065},{"id":"https://openalex.org/keywords/pparalpha","display_name":"PPAR\u03b1","score":0.6710000038146973},{"id":"https://openalex.org/keywords/lipid-lowering-therapy","display_name":"lipid-lowering therapy","score":0.7940000295639038},{"id":"https://openalex.org/keywords/dyslipidemia","display_name":"dyslipidemia","score":0.753000020980835},{"id":"https://openalex.org/keywords/albuminuria","display_name":"albuminuria","score":0.7910000085830688},{"id":"https://openalex.org/keywords/amputation-prevention","display_name":"amputation prevention","score":0.6169999837875366},{"id":"https://openalex.org/keywords/macular-edema","display_name":"macular edema","score":0.7839999794960022},{"id":"https://openalex.org/keywords/proliferative-retinopathy","display_name":"proliferative retinopathy","score":0.875},{"id":"https://openalex.org/keywords/fieldwork","display_name":"fieldwork","score":0.49399998784065247}],"concepts":[{"id":"https://openalex.org/C2778110834","wikidata":"https://www.wikidata.org/wiki/Q419724","display_name":"Fenofibrate","level":2,"score":0.9169173240661621},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8238751292228699},{"id":"https://openalex.org/C2776933373","wikidata":"https://www.wikidata.org/wiki/Q424744","display_name":"Fibrate","level":3,"score":0.7122566103935242},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7022933959960938},{"id":"https://openalex.org/C2778096610","wikidata":"https://www.wikidata.org/wiki/Q1476525","display_name":"Dyslipidemia","level":3,"score":0.6833534240722656},{"id":"https://openalex.org/C2778313320","wikidata":"https://www.wikidata.org/wiki/Q550455","display_name":"Retinopathy","level":3,"score":0.6082320809364319},{"id":"https://openalex.org/C2779829184","wikidata":"https://www.wikidata.org/wiki/Q631361","display_name":"Diabetic retinopathy","level":3,"score":0.587581217288971},{"id":"https://openalex.org/C2781184683","wikidata":"https://www.wikidata.org/wiki/Q1054718","display_name":"Nephropathy","level":3,"score":0.5697958469390869},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5614921450614929},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5505960583686829},{"id":"https://openalex.org/C2776174234","wikidata":"https://www.wikidata.org/wiki/Q974792","display_name":"Albuminuria","level":3,"score":0.5018131732940674},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.43459394574165344},{"id":"https://openalex.org/C2778270857","wikidata":"https://www.wikidata.org/wiki/Q2723972","display_name":"Lipid profile","level":3,"score":0.41738513112068176},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.2944354712963104}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000960","descriptor_name":"Hypolipidemic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000960","descriptor_name":"Hypolipidemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D002995","descriptor_name":"Clofibric Acid","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D002995","descriptor_name":"Clofibric Acid","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003925","descriptor_name":"Diabetic Angiopathies","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D003928","descriptor_name":"Diabetic Nephropathies","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D003929","descriptor_name":"Diabetic Neuropathies","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011345","descriptor_name":"Fenofibrate","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011345","descriptor_name":"Fenofibrate","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.2174/138161209787315701","doi":"https://doi.org/10.2174/138161209787315701","is_oa":false,"landing_page_url":"https://doi.org/10.2174/138161209787315701","pdf_url":null,"source":{"id":"https://openalex.org/S55674637","display_name":"Current Pharmaceutical Design","issn_l":"1381-6128","issn":["1381-6128","1873-4286"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Pharmaceutical Design","raw_type":"journal-article"},{"id":"pmid:19199980","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19199980","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current pharmaceutical design","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2076171551","https://openalex.org/W2063909341","https://openalex.org/W2051336160","https://openalex.org/W2187478359","https://openalex.org/W2611577428","https://openalex.org/W4413418777","https://openalex.org/W4412758073","https://openalex.org/W2150384268","https://openalex.org/W2097819366","https://openalex.org/W2409794848"],"abstract_inverted_index":{"Fibrates":[0],"are":[1,24,92,136],"widely":[2],"prescribed":[3],"lipid-lowering":[4],"drug":[5],"in":[6,28,40,46,125,139,153,161,168,173,179,183,186,197,203,214],"the":[7,93,108,126,140,158,162,169,180,198,215,269],"treatment":[8,191,220,231],"of":[9,53,97,110,130,142,149,218,241,252,273],"dyslipidemia.":[10],"Their":[11],"main":[12],"clinical":[13],"effects,":[14],"mediated":[15],"by":[16],"peroxisome":[17],"proliferative":[18,226],"activated":[19],"receptor":[20],"(PPAR)":[21],"alpha":[22],"activation,":[23],"a":[25,37,122,146,193],"moderate":[26],"reduction":[27,39,196],"total":[29],"cholesterol":[30,34,49],"and":[31,43,57,70,90,103,128,206,211,225,238,261],"low-density":[32],"lipoprotein":[33,48],"(LDL-C)":[35],"levels,":[36],"marked":[38],"triglycerides":[41],"(TG)":[42],"an":[44,166],"increase":[45],"high-density":[47],"(HDL-C),":[50],"usually":[51],"dependent":[52],"their":[54,104,154],"baseline":[55],"levels":[56],"dyslipidemia":[58],"type.":[59],"A":[60],"beneficial":[61],"effect":[62],"on":[63,68,255],"cardiovascular":[64,111],"outcomes":[65],"but":[66],"also":[67,137],"inflammatory":[69],"thrombogenesis":[71],"pathways":[72],"as":[73,75],"well":[74],"antioxidant":[76],"properties":[77],"have":[78],"been":[79],"evidenced":[80],"conferring":[81],"other":[82,118],"pleiotropic":[83],"effects":[84,254],"to":[85,164,267],"fibrates.":[86],"Diabetic":[87],"retinopathy,":[88,210],"nephropathy":[89],"neuropathy":[91],"major":[94],"microvascular":[95,143,256],"complications":[96,272],"Type":[98],"2":[99],"diabetes":[100],"mellitus":[101],"(T2DM)":[102],"presence":[105],"can":[106],"accentuate":[107],"risk":[109,119,240],"disease.":[112],"Hyperglycemia,":[113],"hypertension,":[114],"genetic":[115],"susceptibility":[116],"among":[117],"factors":[120],"play":[121],"significant":[123,194],"role":[124],"development":[127],"progression":[129,237],"these":[131],"complications.":[132],"Plasma":[133],"lipid":[134,150],"abnormalities":[135],"involved":[138],"pathogenesis":[141],"diseases":[144],"suggesting":[145],"potential":[147],"benefit":[148],"lowering":[151],"drugs":[152],"prevention.":[155],"Clofibrate":[156],"was":[157,232],"first":[159,216],"fibrate":[160],"60's":[163],"show":[165],"improvement":[167],"retinal":[170],"hard":[171],"exudation":[172],"subjects":[174],"with":[175,205,234,249],"diabetic":[176,209],"retinopathy.":[177,227],"Recently,":[178],"Fenofibrate":[181],"Intervention":[182],"Event":[184],"Lowering":[185],"Diabetes":[187],"(FIELD)":[188],"study":[189],"fenofibrate":[190,230],"demonstrated":[192],"30%":[195],"need":[199],"for":[200,221],"laser":[201,219],"therapy":[202],"patients":[204],"without":[207],"known":[208],"more":[212],"particularly":[213,262],"course":[217],"both":[222],"macular":[223],"edema":[224],"In":[228],"addition,":[229],"associated":[233],"less":[235],"albuminuria":[236],"reduced":[239],"non":[242],"traumatic":[243],"distal":[244],"amputations.":[245],"These":[246],"results,":[247],"along":[248],"previous":[250],"evidence":[251],"positive":[253],"complications,":[257],"suggest":[258],"that":[259],"fibrates,":[260],"fenofibrate,":[263],"offer":[264],"good":[265],"opportunity":[266],"prevent":[268],"most":[270],"serious":[271],"diabetes.":[274]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":9},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":6}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}